Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-C182A in advanced gastric and pancreatic cancer
NCT03890198Phase 1Terminated
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of LCAR-C182A in gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Number of Participants With Adverse Events, Maximum Tolerated Dose / Recommended Phase 2 Dose and 3 more. Started Apr 2019; status: terminated.
02
Drugs
LCAR-C182A
03
Conditions
gastric cancer (GC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03890198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890198.